Your browser doesn't support javascript.
loading
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine, Eric; Ledermann, Jonathan A; Selle, Frédéric; Gebski, Val; Penson, Richard T; Oza, Amit M; Korach, Jacob; Huzarski, Tomasz; Poveda, Andrés; Pignata, Sandro; Friedlander, Michael; Colombo, Nicoletta; Harter, Philipp; Fujiwara, Keiichi; Ray-Coquard, Isabelle; Banerjee, Susana; Liu, Joyce; Lowe, Elizabeth S; Bloomfield, Ralph; Pautier, Patricia.
Afiliación
  • Pujade-Lauraine E; Medical Oncology Department, Université Paris Descartes, AP-HP, Paris, France. Electronic address: epujade@arcagy.org.
  • Ledermann JA; Department of Oncology, University College London, London, UK.
  • Selle F; Hôpital Tenon, Paris, France.
  • Gebski V; Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW, Australia.
  • Penson RT; Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA.
  • Oza AM; Princess Margaret Cancer Centre, Toronto, Canada.
  • Korach J; Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel.
  • Huzarski T; Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Poveda A; Instituto Valenciano de Oncología, Valencia, Spain.
  • Pignata S; Istituto Tumori Pascale di Napoli, Naples, Italy.
  • Friedlander M; Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia.
  • Colombo N; Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncología, Milan, Italy.
  • Harter P; Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
  • Fujiwara K; Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Ray-Coquard I; Medical Oncology Department, Centre Léon Bérard and University Claude Bernard, Lyon, France.
  • Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK.
  • Liu J; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lowe ES; AstraZeneca, Gaithersburg, MD, USA.
  • Bloomfield R; AstraZeneca, Cambridge, UK.
  • Pautier P; Gustave Roussy Cancer Campus, Villejuif, France.
Lancet Oncol ; 18(9): 1274-1284, 2017 09.
Article en En | MEDLINE | ID: mdl-28754483
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Quimioterapia de Mantención / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Quimioterapia de Mantención / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article